Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

919 - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Surgical Oncology;  Colon and Rectal Cancer

Presenters

Dominik Modest

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

D.P. Modest1, V. Heinemann2, G. Folprecht3, T. Denecke4, J. Pratschke5, H. Lang6, M. Bemelmans7, T. Becker8, M. Rentsch9, D. Seehofer10, C. Bruns11, B. Gebauer12, S. Held13, U. Neumann14, I. Ricard15

Author affiliations

  • 1 Medical Department Iii, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 2  department Of Medical Oncology And Comprehensive Cancer Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 3 University Cancer Center, Medical Dept. I  , Universitätsklinikum Dresden, 01307 - Dresden/DE
  • 4 Klinik F. Radiologie, Charite, 13353 - Berlin/DE
  • 5 Chirugie, Charite, 13353 - Berlin/DE
  • 6 Chirugie, Uniklinik Mainz, 55131 - Mainz/DE
  • 7 Chirurgie, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 8 Klinik F. Allgemeine-, Viszeral-, Thorax-, Transplantations- Und Kinderchirurgie, Uniklinikum Schleswig-Holstein, 24105 - Kiel/DE
  • 9 Chirurgie, LMU Großhadern, 81377 - München/DE
  • 10 Chirugie, Uniklinik Leipzig, 04103 - Leipzig/DE
  • 11 Chirurgie, Uniklinik Köln, 50937 - Köln/DE
  • 12 Radiologie, Charite, 13353 - Berlin/DE
  • 13 Statistik, Clinassess, 51379 - Leverkusen/DE
  • 14 Chirurgie, Universitaetsklinikum Aachen (UKA), 52074 - Aachen/DE
  • 15 Biometrie, IBE München, 81377 - München/DE
More

Resources

Abstract 919

Background

Paired tumor evaluations before randomization and at best response (nadir) of 270 patients with RAS WT tumors treated with first-line therapy with cetuximab (cet) vs. bevacizumab (bev)- in combination with FOLFIRI were reviewed for resectability of metastates. We assessed parameters influencing resectability, conversion to resectability and survival after nadir.

Methods

Baseline information and resectability were correlated with Fisher’s exact tests. Conversion to resectability was defined as unresectable disease before randomization and resectable disease at nadir. Univariate and multivariate logistic models were fitted with resectability at nadir as response variable. A Cox model comparing the survival from nadir was used to measure the influence of treatment, resectability at nadir and resection (time dependent variable). Interaction of resection and treatment arm on survival was tested by likelihood ratio test.

Results

Initial Lung metastases (OR = 0.35 95% CI = (0.19 - 0.63), p = 0.001), BRAF mutation (OR = 0.33 95% CI = (0.12-0.82), p = 0.03) and high alkaline phosphatase (OR = 0.51, 95% CI = (0.31-0.81), p = 0.006) were associated with less chance of conversion to resectability and in case of lung metastases also of being resected if resectability at nadir was observed (OR = 0.33, 95% CI = (0.08-1.04) p = 0.046). Early tumor shrinkage (=ETS: -20% tumor diameter after 6 weeks therapy) and depth of response (DpR) were associated with conversion to resectability (ETS: OR = 1.86, 95% CI = (1.06-3.3), p = 0.034, DpR: OR = 1.02, 95% CI = (1.01-1.03), p < 0.001). Metastatic resection improved post-nadir survival (HR = 0.53, 95% CI = (0.29- 0.97), p = 0.04). This was pronounced in cet-treated patients as compared to bev-treated patients (HR (cet)=0.17, 95% CI = (0.04-0.69), p = 0.01; HR (bev)=0.89, 95% CI = (0.47-1.69), p = 0.73; interaction test p = 0.02).

Conclusions

Conversion to resectability is associated with baseline characteristics like lung metastases and BRAF mutation as well as with early efficacy parameters (ETS, DpR). In FIRE-3, resection of metastases was associated with improved post-nadir survival, this effect originated predominantly from the cetuximab-based study arm.

Clinical trial identification

NCT00433927.

Legal entity responsible for the study

Klinikum der Universität (LMU), Munich, Germany.

Funding

Merck Serono.

Editorial Acknowledgement

Disclosure

D.P. Modest: Grants: Merck KGaA, Pfizer, Visage Imaging, during the conduct of the study; Grants and personal fees: Merck KGaA, Amgen, Roche, Bayer; Grants: Sanofi, outside the submitted work. V. Heinemann: Grants: Merck, Pfizer during the conduct of this study, Grants: Amgen, Roche, Sanofi Sirtex outside the submitted work. G. Folprecht: Honoraries: Roche/Genentech, Bayer, Amgen, Lilly and Servier, Study grant, Honoraries: Merck-Serono, outside the submitted work. T. Denecke: Grants and personal fees: Bayer and B.E Imaging; Personal fees: Toshiba, Novartis, Ipsen and Parexel; Grants, personal fees and non-financial support: Siemens, GE; Grants: Guerbet; Non-financial support: Visage Imaging, outside the submitted work. C. Bruns: Personal fees: Merck, Sirtex, Grant: Celgene, outside the submitted work B. Gebauer: Personal fees: Merck KGaA, Pfizer; Personal fees, Study support: Visage Imaging, during the conduct of the study; Personal fees: Parexel, C.R. Bard, Sirtex Medical, Roche, Merck, Bayer, Icon, Ipsen, Siemens outside the submitted work; Travel support: Cook Medical, 3M, St Jude Medical; Travel and study support: AngioDynamics; Study support: Philips, outside the submitted work U. Neumann: Study grant: Merck during the conduct of the study; Study grant and personal fees: Merck outside the submitted work; Personal fees: Roche, Amgen, Novartis, Chiesi and Astellas during the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.